There was a step forward and a step backward last week related to GRAIL, the company seeking to develop a simple DNA blood test to detect most forms of cancer early enough to be effectively treated.
The step backward came from Illumina (NASDAQ:ILMN), GRAIL’s primary founder. GRAIL repurchased part of the genomic-sequencing leader’s stake in the company. Bristol-Myers Squibb (NYSE:BMY), on the other hand, took a step forward by making a significant investment in GRAIL. What do these recent moves mean for Illumina and Bristol-Myers Squibb investors?
